Yinyi/Yinyi intravascular stent and Qingzhou/Bingo intravascular catheter were rated as Dalian Famous Brand Products.
Yinyi Biopharmaceutical Elution Balloon Catheter (Registration Certificate No.: National Machinery Note 20173771535) was selected into the "Innovative Medical Device Product Catalog (2018)" of the Ministry of Science and Technology.
The company was invited to attend the 2018 12th China Consumer Economy High-level Forum and China Pharmaceutical Industry Future Development Summit, and was awarded the China Medical Device Quality Award.
The company was appraised by the Liaoning Provincial Industry and Information Commission as a "Professional, Specialized, New" Enterprise in 2018.
The company's self-developed and innovative product, drug eluting balloon catheter, was appraised by the Liaoning Provincial Industry and Information Committee as the "Specialized, Special-New" product technology in 2018.
The company passed the high-tech enterprise certification again.
The company participated in the first China Independent Brand Expo and China Brand Development International Forum held in Shanghai. As an exhibitor in the Dalian region, Yinyi Bio will showcase the world's first drug balloon for coronary bifurcation lesions and the world's first carrier-free microblind heart stent.
The company completed the industrial and commercial change registration procedures for increasing the registered capital and obtained the new business license after the change. After this change, the company's registered capital increased from RMB 128,088,900 to RMB 137,014,552.
From March 22nd to March 25th, the 16th China Interventional Cardiology Conference (CIT2019). During the conference, the company held a "Qingzhou" drug balloon bifurcation treatment forum. The forum invites many well-known experts in the field of coronary intervention to discuss the latest clinical progress of drug balloons, share wonderful cases of bifurcation lesions treated with drug balloons, and look forward to the future development of interventional therapy.
The National Development and Reform Commission, Dalian Development and Reform Commission, and Jinpu New District Economic Development Bureau have successively approved the establishment of a national and local joint engineering research center for biomedical materials research and development technology.
During the Interventional Salon of Jiuhua Villa in Beijing, a national launch meeting for the "Qingzhou Drug Eluting Balloon Catheter" was held.
In Dalian Conrad Hotel, a press conference for the launch of "Qingzhou Drug Eluting Balloon Catheter" was held and the first batch of strategic cooperation signing ceremony was held.
Wabei New Third Board Research Institute released "April 2017, Liaoning New Third Board Enterprise Market Value TOP100, Yinyi Biology ranked 12th.
Wabei New Third Board Research Institute released the "2016 New Third Board Top 100 Most Innovative Enterprises" list, and Yinyi Biology ranked 41st.
Yinyi Biotech held the 2016 annual management review meeting in the company's headquarters.
Yinyi Biological held the 2016 fire drill and escape drill at the company headquarters.
Yinyi Biology sent staff to participate in the 13th Dalian International Symposium on New Advances in Diagnosis and Treatment of Coronary Heart Disease in Dalian.
Yinyi Biotechnology completed all the follow-up work of the Qingzhou drug balloon clinical trial (bifurcation lesion project).
Yinyi Biotech sent staff to participate in the second council of the third session of the surgical implant professional committee of China Medical Device Industry Association in Beijing.
The State Food and Drug Administration conducted an "flying inspection" on the implementation of Yinyi Biotech's "Medical Device Manufacturing Quality Management Regulations".
The authoritative list of China's NEEQ innovative brands, co-sponsored by AsiaBrand.com and Xinhuanet.com, was announced, and Yinyi Bio was ranked 80th.
Yinyi Biology sent staff to participate in the "2016 New Third Edition Top 100 Brands" conference held in Beijing.
The China-Israel Foundation and the Israeli delegation visited the Yinyi Biological Headquarters and the International Innovation Industrial Park for Class III Medical Devices in Double D Port.
The Israel Innovation Investment Conference hosted by Yinyi Biotechnology was held at Dalian Xinghai Expo Exhibition Center.
The provisional board of directors of Yinyi Biology was held in Dalian headquarters.
Liaoning Provincial Pharmaceutical Certification Center conducted an on-site investigation on the implementation of the inspection work of Yinyi's biomedical device registration system.
Yinyi Biotech held a semi-annual meeting of sales managers in Dalian headquarters.
The Liaoning Provincial Pharmaceutical Certification Center has conducted a new product registration system inspection on Yinyi Biologics "Contrast Catheter" in accordance with the "Medical Device Manufacturing Quality Management Regulations".
The "2016 Liaoning New Third Board Listed Enterprises Top 100 Total Assets Ranking" released by the China Business Industry Research Institute, Yinyi Biology ranked 22nd.
Liaoning Provincial Food and Drug Administration conducts on-site supervision and inspection of Yinyi biological production quality management.
Yinyi Biotech participated in the "Eleventh Oriental Cardiology Conference" held at the Shanghai World Expo Center.
The "contrast catheter" independently researched and developed by Yinyi Biotechnology is submitted to the national new product registration.
Beijing National Medical Equipment Huaguang Certification Co., Ltd. conducts annual supervision and review of the quality management system of Yinyi Biological.
Yinyi Biology participated in the "Nineteenth National Interventional Heart Disease Forum" held in Shijiazhuang, Hebei.
Yinyi Bio-Bio held its 2015 annual sales meeting in Dalian headquarters.
Yinyi Bio will participate in the "18th Southern International Cardiovascular Conference".
Yinyi Biopharmaceuticals completed the first financing of 6512204 million yuan after the listing of "New Third Board", which provided necessary capital supplement for the company's development.
Yinyi Biotech participated in the "Fifteenth China Interventional Cardiology Conference" held at the Beijing National Convention Center.
Yinyi Bio-Bio held the 2015 year-end summary and recognition meeting.
Yinyi Biological participated in the "7th Clinical Cardiovascular Disease Conference and the 13th China Coronary Intervention Salon" in Beijing.
The company's "New Third Board" was officially listed. The stock abbreviation is "Yinyi Bio", the stock code: 835066.
Our company has obtained the 3A certificate of integrity tax payment
The balloon dilatation catheter was approved by SFDA for marketing
Polymer-free drug heart stent was approved for marketing in Thailand
Won the national "Twelfth Five-Year" science and technology support plan project
Obtained the special plan project of the national old industrial base structure adjustment
Recognized as Liaoning Provincial Enterprise Technology Center
Is recognized as a national innovative pilot enterprise
The coronary metal stent system obtained CE certification
Balloon dilatation catheter obtained CE certification
Identified as an enterprise post-doctoral scientific research base in Liaoning Province
Polymer-free drug heart stent won the first prize of Dalian Technology Invention
The new version of the quality system passed the annual on-site audit by Beijing National Medical Equipment Huaguang Certification Co., Ltd.
The one-year follow-up results of the SERY study were announced for the first time at the Great Wall International Cardiology Conference
Our company was approved as a member of Liaoning Medical Device Industry Association
Won the Dalian Independent Innovation Product Certificate
The new pipe net-shaped stent has obtained the national authorized invention patent
Polymer-free drug-carrying stent obtained national authorized invention patent
Identified as a national high-tech enterprise
The first polymer-free drug heart stent in China was approved by SFDA for marketing
Obtained the National "Eleventh Five-Year" Science and Technology Support Program Project
Obtained the national high-tech industrialization demonstration project
Won the National 863 Program Project
Registered and established a scientific and technological achievement transformation entity-Liaoning Biomedical Materials R&D Center Co., Ltd.
The coronary metal stent system was approved by SFDA for marketing
Won the National "Tenth Five-Year Plan" Science and Technology Project
Won the National Technology Innovation Fund Project for Small and Medium-sized Enterprises
Liaoning Provincial Biomedical Materials R&D Center was established with the approval of the Liaoning Provincial Department of Science and Technology
The coronary metal stent is approved by SFDA for marketing